ANI Pharmaceuticals ANIP Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's retained earnings?
- ANI Pharmaceuticals (ANIP) reported retained earnings of $6.39M in Q1 2026.
- How has ANI Pharmaceuticals's retained earnings changed year-over-year?
- ANI Pharmaceuticals's retained earnings increased by 107.5% year-over-year, from -$85M to $6.39M.
- What is the long-term trend for ANI Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's retained earnings has grown at a 36.0% compound annual growth rate (CAGR), from -$4.97M to -$23.1M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.